论文部分内容阅读
目的观察瑞舒伐他汀对扩张性心肌病(DCM)心力衰竭患者心功能及血清肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)水平的影响。方法选择DCM心力衰竭患者67例,随机分为治疗组(34例)及对照组(33例)。对照组给予常规纠正心力衰竭药物治疗,治疗组在常规治疗基础上加用瑞舒伐他汀10mg,每晚1次。治疗前及治疗6个月后进行心脏彩超检查,测定左心室舒张末内径(LVEDd)、左心室射血分数(LVEF),测定血清TNF-α、IL-6浓度。结果两组患者治疗6个月时LVEDd均较治疗前显著缩小(P<0.05),LVEF较治疗前显著提高(P<0.05)。治疗6个月时治疗组与对照组比较:LVEF较对照组显著提高(P<0.05),LVEDd有进一步缩小趋势,但差异无统计学意义。治疗6个月时,治疗组血清TNF-α[(149.76±1.16)和(177.76±1.39),P<0.05]、IL-6[(24.37±1.45)和3(2.37±1.55),P<0.05]水平较治疗前显著下降,对照组较治疗前无明显变化。结论瑞舒伐他汀可明显改善DCM心力衰竭患者心功能,降低血清TNF-α、IL-6水平,有利于DCM的治疗。
Objective To observe the effects of rosuvastatin on cardiac function, serum levels of tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in patients with dilated cardiomyopathy (DCM) Methods 67 patients with DCM heart failure were randomly divided into treatment group (34 cases) and control group (33 cases). The control group was given conventional remedy of heart failure. The treatment group was given rosuvastatin 10 mg on a regular basis, once a night. Echocardiography was performed before treatment and 6 months after treatment. Left ventricular end-diastolic diameter (LVEDd) and left ventricular ejection fraction (LVEF) were measured. Serum levels of TNF-α and IL-6 were measured. Results LVEDd was significantly reduced (P <0.05) and LVEF was significantly increased (P <0.05) in both groups at 6 months after treatment. At 6 months after treatment, the LVEF in treatment group was significantly higher than that in control group (P <0.05), LVEDd was further reduced, but the difference was not statistically significant. The levels of TNF-α in the treatment group (149.76 ± 1.16 and 177.76 ± 1.39, P <0.05, IL-6 [24.37 ± 1.45 and 3 (2.37 ± 1.55 and P <0.05 ] Levels were significantly lower than before treatment, no significant change in the control group before treatment. Conclusion Rosuvastatin can significantly improve cardiac function in patients with heart failure, reduce serum TNF-α, IL-6 levels, is conducive to the treatment of DCM.